Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at imiquimod cream as treatment for an early type of melanoma skin cancer (LIMIT - 1)
This trial looked at imiquimod cream to treat an early type of melanoma skin cancer called lentigo maligna.
More about this trial
- how well imiquimod cream worked to treat people with lentigo maligna
- how well people accepted using the cream
- what people thought about using imiquimod cream
- if taking a sample of tissue (biopsy) after imiquimod can tell doctors if the treatment has worked
- if it would be worthwhile to do a phase 3 trial comparing lentigo malinga to surgery
Summary of results
- their doctor couldn’t see any sign of lentigo malinga
- samples of tissue (biopsies) taken from where their lentigo maligna was showed no sign of it
- imiquimod cream cures everyone (100%) and surgery cures 95 out of every 100 people (95%)
- imiquimod cream cures 10 out of every 100 people (10%) to surgery cures 95 out of every 100 people (95%)
The higher the supposed cure rate of imiquimod cream the more people said it would be their first choice of treatment.
Half the people said they would choose surgery over imiquimod cream even when the cure rate of imiquimod cream was 85 out of every 100 people (85%).
The trial team concluded that imiquimod cream didn’t work well enough to do a larger phase 3 trial to compare it with surgery.
Where we got this information from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Jerry Marsden
NIHR Research for Patient Benefit (RfPB) Programme
NIHR Clinical Research Network: Cancer
University Hospital Birmingham NHS Foundation Trust